个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
张太平,男,北京协和医院基本外科教授,主任医师,博士生导师。1995年获中国协和医科大学外科学博士学位,2002年4月在美国匹兹堡大学Starzl器官移植研究所做访问学者,2002年5月至2004年12月在美国北卡罗来纳大学基因治疗中心做博士后研究。目前担任中国研究型医院学会胰腺疾病专业委员会主任委员,中国研究型医院学会加速康复外科医学专业委员会副主任委员;中国研究型医院学会普通外科分会副主任委员;中国医师协会胰腺病学专业委员会副主任委员;中华医学会外科学分会常委兼副秘书长;外科手术学组副组长;美国外科学院会员(FACS);国际外科学会会员。《中华肝胆外科杂志》、《中华胰腺病学杂志》、《中华普通外科手术学杂志电子版》和《中华肝脏外科手术学电子杂志》副主编,《中华外科杂志》、《中华普通外科杂志》、《中华消化外科杂志》、《中国实用外科杂志》、《外科理论与实践》、《临床肝胆病杂志》、《中华疝与腹壁外科杂志电子版》、《国际外科杂志》等杂志编委。《Annals of Surgical Oncology》、《中华医学杂志》、《中华外科杂志》特约审稿专家。国家自然科学基金、科技部支撑计划、首发基金、教育部留学基金、人事部留学基金评审专家。擅长胰腺、胃肠、胆道、甲状腺疾病尤其是复杂的胰腺癌、胰腺神经内分泌肿瘤、胰腺囊性肿瘤等病例的外科诊治。长期从事胰腺外科的临床与基础研究,主要研究方向为胰腺癌早期诊断和化疗耐药,获得国家十二五科技支撑项目、973、国家自然科学基金、教育部博士点基金等多项基金资助。发表论文及综述300余篇,参加专著和教材编写30余部,作为主编助理出版的《胰腺病学》获国家新闻出版署优秀图书出版工程,以第二和第三完成人获得国家科技进步二等奖各一项、北京市科技进步一等奖、中华医学科技奖一等奖、教育部科技进步二等奖等国家级、省部级奖励10余项。
团队简介
Team Profile
申请人在赵玉沛院士带领下,长期从事胰腺疾病的基础与临床研究,先后获得国家科技支撑计划、973项目、国家重点研发计划等项目资助,构建了包括胰腺癌PDX模型、类器官药筛平台、个体化条件重编程等在内的胰腺癌体外药筛体系及化疗耐药分子调控网络,探索了胰腺癌化疗耐药机制和治疗靶点,在 Journal of Hematology & Oncology、Molecular Cancer、Clinical Cancer Research、Annals of Surgery等国内外期刊发表论文 300余篇,获得发明专利授权 5项。以第二和第三完成人先后获国家科技进步二等奖两次,以及中华医学科技一等奖、教育部科技成果二等奖和北京市科技成果一等奖等国家级、省部级奖励 10余项。围绕胰腺疾病的临床诊治,申请人牵头了多项多中心临床研究,在胰腺癌新辅助治疗、辅助治疗、胰腺围术期管理等多个方面积累了丰富的研究经验,研究成果被相关指南引用。作为国内胰腺疾病领域的知名专家,担任中国研究型医院学会胰腺疾病专委会主任委员、中华医学会外科学分会常委兼副秘书长及手术学组副组长、中国医师协会胰腺病专委会副主任委员、中华肝胆外科杂志和中华胰腺病学杂志副主编,先后牵头和执笔指南及专家共识近 10部,涵盖了胰腺疾病诊断、手术治疗、围术期管理、胰腺癌新辅助治疗等多个方面,推动了我国胰腺疾病诊治的规范化。申请人先后参与教材及专著编写 30余部,培养各类研究生、博士后 50余人。
硕士研究生 2 名,博士研究生 6 名
# | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
---|---|---|---|---|---|
1 | PGM3 抑制剂作为胰腺导管腺癌创新疗法的临床前评估 | 2020-01-01 —— 2022-12-31 | 180.0 | 主持在研的国家或省部级科研项目 | 主持者 |
2 | MYC/let-7/LAT2通路通过谷氨酰胺代谢和糖酵解调控胰腺癌化疗耐药的机制研究 | 2020-01-01 —— 2023-12-01 | 55.0 | 主持在研的国家或省部级科研项目 | 主持者 |
3 | PGM3抑制剂作为胰腺导管腺癌创新疗法的临床前评估 | 2020-01-01 —— 2022-12-01 | 主持在研的国家或省部级科研项目 | 主持人 | |
4 | 国产腔镜手术机器人系统肝胆胰外科临床应用解决方案 | 2023-11-05 —— 2026-10-01 | 主持在研的国家或省部级科研项目 | 主持人 | |
5 | 探究胰腺癌“空间-动态”化疗耐药机制及治疗靶点的研究 | 2023-01-01 —— 2026-12-31 | 主持在研的国家或省部级科研项目 | 主持人 | |
6 | MYC/let-7/LAT2通路通过谷氨酰胺代谢和糖酵解调控胰腺癌化疗耐药的机制研究 | 2020-01-01 —— 2023-12-01 | 主持在研的国家或省部级科研项目 | 主持人 | |
7 | 基于PDTX模型筛选的lncRNAs在胰腺癌化疗耐药调控网络中的作用及机制研究 | 2018-01-01 —— 2021-12-31 | 主持在研的国家或省部级科研项目 | 主持人 | |
8 | 靶向let-7/LAT2/mTOR联合PD-L1单抗对胰腺癌免疫治疗的机制研究 | 2019-01-15 —— 2021-12-15 | 主持在研的国家或省部级科研项目 | 主持人 | |
9 | RARS2-MFN1-BCL2轴通 过调控线粒体动力学介 导胰腺癌化疗耐药的机 制研究 | 2024-01-01 —— 2026-12-31 | 主持在研的国家或省部级科研项目 | 主持人 | |
10 | 3D生物打印类器官药筛在胰腺癌辅助化疗中的临床应用 | 2022-11-01 —— 2025-11-01 | 主持在研的国家或省部级科研项目 | 主持人 | |
11 | 生物3D打印高通量肿瘤类器官技术开发及临床转化研究 | 2023-09-30 —— 2026-09-30 | 主持在研的国家或省部级科研项目 | 主持人 | |
12 | 基于i-CR的胰腺癌快速药筛体系的临床应用 | 2019-11-01 —— 2021-10-01 | 主持的企业/行业委托重大项目 | 主持人 | |
13 | 基于视频的基本外科阶梯式临床及微创教学方案 | 2021-07-01 —— 2023-12-31 | 主持的企业/行业委托重大项目 | 主持人 | |
14 | 基于 i-CR 的胰腺癌快速药筛体系的临床应用 | 2019-11-01 —— 2021-10-31 | 主持的企业/行业委托重大项目 | 主持人 |
# | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
---|---|---|---|---|
1 | Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy | Int Immunopharmacol | 2022-06-10 | 张太平 |
2 | Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study | EBioMedicine | 2022-06-10 | 张太平 |
3 | "The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells" | Cells | 2022-06-11 | 张太平 |
4 | Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target Bim | Oncol Lett | 2022-06-11 | 张太平 |
5 | Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. | molecular cancer | 2022-06-11 | 张太平 |
6 | Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance | Cancer Lett | 2022-06-11 | 张太平 |
7 | WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma | Oncol Lett | 2022-06-11 | 张太平 |
8 | Hexosamine Pathway Inhibition Overcomes Pancreatic Cancer Resistance to Gemcitabine Through Unfolded Protein Response and EGFR-Akt Pathway Modulation | Oncogene | 2022-06-10 | 张太平 |
9 | OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2 | Mol Cancer Res. | 2022-06-11 | 张太平 |
10 | High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma. | Pathology - Research and Practice | 2022-06-11 | 张太平 |
11 | PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value | Journal of Experimental & Clinical Cancer Research | 2022-06-11 | 张太平 |
12 | "Changes in Serum Lactate Level Predict Postoperative Intra- Abdominal Infection After Pancreatic Resection" | World J Surg | 2022-06-11 | 张太平 |
13 | "The dual functional role of MicroRNA?18a (miR?18a) in cancer development" | Clin Trans Med | 2022-06-11 | 张太平 |
14 | A Single Talent Immunogenic Membrane Antigen and Novel Prognostic Predictor: voltage-dependent anion channel 1 (VDAC1) in Pancreatic Cancer. | Sci Rep | 2022-06-11 | 张太平 |
15 | Analysis of clinical characteristics and treatment of pancreatic cystic tumors | Chin J Cancer Res | 2022-06-11 | 张太平 |
16 | Primary Retroperitoneal Ganglioneuroma: A Retrospective Cohort Study of 32 Patients | Front Surg | 2022-06-11 | 张太平 |
17 | "Do novel treatment strategies enhance T cell- mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy" | Int Immunopharmacol | 2022-06-11 | 张太平 |
18 | A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediaterisk patients after pancreaticoduodenectomy | J Gastroenterol | 2022-06-13 | 张太平 |
19 | The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star | Ther Adv Med Oncol | 2022-06-10 | 张太平 |
20 | "Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor" | Cells | 2022-06-11 | 张太平 |
21 | NF-kB in pancreatic cancer: Its key role in chemoresistance | Cancer Letters | 2022-06-11 | 张太平 |
22 | High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis | J Hematol Oncol. | 2022-06-13 | 张太平 |
23 | Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. | J Hematol Oncol. | 2022-06-11 | 张太平 |
24 | Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models | Clin Cancer Res | 2022-06-11 | 张太平 |
25 | The?enhancement?of?glycolysis?regulates?pancreatic?cancer?metastasis. | Cellular and Molecular Life Sciences | 2022-06-11 | 张太平 |
26 | "Role of the microbiome in occurrence, development and treatment of pancreatic cancer" | molecular cancer | 2022-06-11 | 张太平 |
27 | 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. | Cell Res | 2022-06-11 | 张太平 |
28 | Surgeons’ knowledge regarding the diagnosis and management of pancreatic cancer in China: a cross-sectional study | BMC Health Serv Res | 2022-06-11 | 张太平 |
29 | Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors. | Sci Rep | 2022-06-11 | 张太平 |
30 | Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models | Clin Cancer Res | 2022-06-11 | 张太平 |
31 | Current epidemiology of pancreatic cancer: Challenges and opportunities | Chin J Cancer Res | 2022-06-11 | 张太平 |
32 | Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progression Modulated by TUBB/Rho/ROCK Signaling Pathway? A Bioinformatic Analysis | Biomed Res Int. | 2022-06-10 | 张太平 |
33 | Expression, function and clinical application of stanniocalcin-1 in cancer | J Cell Mol Med | 2022-06-10 | 张太平 |
34 | PD-1/PD-L1 and immunotherapy for pancreatic cancer | Cancer Lett | 2022-06-11 | 张太平 |
35 | The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer | Cancer Lett | 2022-06-11 | 张太平 |
36 | MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1. | Neoplasma | 2022-06-11 | 张太平 |
37 | "Novel therapies targeting hypoxia mechanism to treat pancreatic cancer" | Chin J Cancer Res | 2022-06-11 | 张太平 |
38 | "Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer" | Front Oncol. | 2022-06-11 | 张太平 |
39 | "Risk factors and prevention of postoperative pancreatic fistula after insulinoma enucleation:a retrospective study from a high-volume center" | Pancreatology | 2022-06-11 | 张太平 |
40 | "Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine" | Journal of Experimental & Clinical Cancer Research | 2022-06-11 | 张太平 |
41 | "Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatosplenectomy (CDPS) for left-sided pancreatic ductal adenocarcinoma" | Surg Today | 2022-06-11 | 张太平 |
42 | "Pancreatic head cancer: Open or minimally invasive pancreaticoduodenectomy?" | Chinese Journal of Cancer Research | 2022-06-11 | 张太平 |
43 | MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy | Cancer Biol Med | 2022-06-10 | 张太平 |
44 | Is Invagination Anastomosis More Effective in Reducing Clinically Relevant Pancreatic Fistula for Soft Pancreas After Pancreaticoduodenectomy Under Novel Fistula Criteria: A Systematic Review and Meta-Analysis | Front Oncol. | 2022-06-10 | 张太平 |
45 | Mechanistic Target of Rapamycin in the Tumor Microenvironment and Its Potential as a Therapeutic Target for Pancreatic Cancer | Cancer Lett. | 2022-06-11 | 张太平 |
46 | Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. | Cancer Cell Int. | 2022-06-11 | 张太平 |
47 | Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study | Ann Surg | 2022-06-11 | 张太平 |
48 | MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma, | Journal of Experimental & Clinical Cancer Research | 2022-06-11 | 张太平 |
49 | MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations. | Frontiers in Oncology | 2022-06-11 | 张太平 |
50 | Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC) | Cancer Lett. | 2022-06-10 | 张太平 |
51 | Targeting hypoxic tumor microenvironment in pancreatic cancer | J Hematol Oncol. | 2022-06-11 | 张太平 |
52 | MicroRNA-381-A Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in Cancer | Front Oncol. | 2022-06-11 | 张太平 |
53 | Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? | Cancer Medicine. | 2022-06-11 | 张太平 |
54 | CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma | Cellular Oncology | 2022-06-11 | 张太平 |
55 | LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer | Journal of Experimental & Clinical Cancer Research | 2022-06-11 | 张太平 |
56 | Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. | Journal of Hematology & Oncology | 2019-08-16 | 通讯作者 |
57 | OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2 | MOLECULAR CANCER RESEARCH | 2020-05-01 | 通讯作者 |
58 | Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study | EBioMedicine | 2020-04-28 | 通讯作者 |
59 | Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progression Modulated by | Biomed Research International | 2020-05-11 | 通讯作者 |
60 | CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma | Cellular Oncology | 2020-10-01 | 通讯作者 |
61 | Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models | CLINICAL CANCER RESEARCH | 2021-06-13 | 通讯作者 |
62 | HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway | MOLECULAR CARCINOGENESIS | 2022-07-04 | 通讯作者 |
63 | High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis | Journal of Hematology & Oncology | 2021-08-04 | 通讯作者 |
64 | A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediaterisk patients after pancreaticoduodenectomy | JOURNAL OF GASTROENTEROLOGY | 2021-08-28 | 通讯作者 |
65 | Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer | frontiers in cell and developmental biology | 2021-09-07 | 通讯作者 |
66 | Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cance | Frontiers in Oncology | 2021-05-07 | 通讯作者 |
67 | Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study | BRITISH JOURNAL OF SURGERY | 2022-11-11 | 通讯作者 |
68 | Cancer-specific survival and metastasis in pancreatic mucinous cystadenocarcinoma: A SEER-based cohort study | Frontiers in Oncology | 2022-10-20 | 通讯作者 |
69 | mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/ +LSL-KrasG12D/+Pdx-1-Cre murine models | CANCER LETTERS | 2023-02-01 | 通讯作者 |
70 | Primary tumor resection enhances the survival of pancreatic neuroendocrine carcinoma patients with liver metastasis under the definition of 2019 WHO classification | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023-05-15 | 通讯作者 |
71 | Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023-01-25 | 通讯作者 |
72 | Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis | FRONTIERS IN ONCOLOGY | 2022-11-23 | 通讯作者 |
73 | Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patients | Frontiers in Surgery | 2022-10-11 | 通讯作者 |
74 | Targeting hypoxic tumor microenvironment in pancreatic cancer | Journal of Hematology & Oncology | 2021-01-01 | 通讯作者 |
75 | Do novel treatment strategies enhance T cell-mediated immunity: Opportunities and challenges in pancreatic cancer immunotherapy | INTERNATIONAL IMMUNOPHARMACOLOGY | 2020-11-01 | 通讯作者 |
76 | Current epidemiology of pancreatic cancer:challenges and opportunities | Chinese Journal of Cancer Research | 2020-10-01 | 通讯作者 |
77 | Novel therapies targeting hypoxia mechanism to treat pancreatic cancer | Chinese Journal of Cancer Research | 2020-12-01 | 通讯作者 |
78 | Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer | Cancer Cell International | 2022-04-07 | 通讯作者 |
79 | MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy | CANCER BIOLOGY & MEDICINE | 2020-08-01 | 通讯作者 |
80 | The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2020-07-01 | 通讯作者 |
81 | Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC) | CANCER LETTERS | 2020-10-01 | 通讯作者 |
82 | Pancreatic head cancer: Open or minimally invasive pancreaticoduodenectomy? | CHINESE JOURNAL OF CANCER RESEARCH | 2019-12-01 | 通讯作者 |
83 | The dual functional role of MicroRNA-18a (miR-18a) in cancer development | CLINICAL AND TRANSLATIONAL MEDICINE | 2019-12-01 | 通讯作者 |
84 | Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. | CANCER LETTERS | 2020-08-01 | 通讯作者 |
85 | Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? | Cancer Medicine | 2019-10-01 | 通讯作者 |
86 | Is Invagination Anastomosis More Effective in Reducing Clinically Relevant Pancreatic Fistula for Soft Pancreas After Pancreaticoduodenectomy Under Novel Fistula Criteria | Frontiers in Oncology | 2020-08-01 | 通讯作者 |
87 | Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory | Cancer Cell International | 2020-03-04 | 通讯作者 |
88 | Role of the microbiome in occurrence, development and treatment of pancreatic cancer | Molecular Cancer | 2019-12-01 | 通讯作者 |
89 | MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations | FRONT ONCOL | 2019-09-01 | 通讯作者 |
90 | The enhancement of glycolysis regulates pancreatic cancer metastasis | CELLULAR AND MOLECULAR LIFE SCIENCES | 2019-08-20 | 通讯作者 |
91 | Expression, function and clinical application of stanniocalcin-1 in cancer | JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | 2020-05-01 | 通讯作者 |
92 | Comprehensive study of clinical features, prognostic factors, and survival in patients with pancreatic solid pseudopapillary neoplasms based on the 2019 WHO classification | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023-07-21 | 通讯作者 |
93 | Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis. | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023-07-26 | 通讯作者 |
94 | Local resection for solid pseudopapillary neoplasms of the pancreas shows improved postoperative gastrointestinal function and reduced mental stress: a multiquestionnaire survey from a large cohort | International Journal of Surgery | 2023-12-01 | 通讯作者 |
95 | Impact of Combined Chemotherapy and Targeted Therapy on Pancreatic Neuroendocrine Carcinoma with Liver Metastasis: A Single-Center Modified Nomogram Analysis | OncoTargets and Therapy | 2024-06-22 | 通讯作者 |
96 | Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer | Cancer Management and Research | 2024-05-21 | 通讯作者 |
97 | FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis | CANCER RESEARCH | 2024-05-22 | 通讯作者 |
98 | Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer | npj Genomic Medicine | 2024-05-20 | 通讯作者 |
99 | E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation | FREE RADICAL BIOLOGY AND MEDICINE | 2024-05-18 | 通讯作者 |
100 | The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3 | iscience | 2024-04-19 | 通讯作者 |
101 | Solid pseudopapillary neoplasm (SPN) of the pancreas: current understanding on its malignant potential and management | Discover Oncology | 2024-03-18 | 通讯作者 |
102 | Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment | CHIN MED J | 2024-04-08 | 通讯作者 |
103 | Ribosome profiling: a powerful tool in oncological research | Biomarker Research | 2024-01-25 | 通讯作者 |
104 | The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks | CANCER LETTERS | 2024-05-16 | 通讯作者 |
105 | Epidemiology of pancreatic cancer: New version, new vision | Chinese Journal of Cancer Research | 2023-12-01 | 通讯作者 |
106 | Organoid: Bridging the gap between basic research and clinical practice | CANCER LETTERS | 2023-12-18 | 通讯作者 |
107 | Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. | CANCER LETTERS | 2023-11-18 | 通讯作者 |
108 | Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC) | HELIYON | 2023-10-17 | 通讯作者 |
109 | From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment | CELLULAR ONCOLOGY | 2023-09-19 | 通讯作者 |
110 | Cancer-associated fibroblasts: A key target to snatch victory from defeat in therapy resistance associated with the pancreatic cancer stroma. | CANCER LETTERS | 2023-07-28 | 通讯作者 |
# | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2015-254 | 胰岛素瘤诊治体系的建立及临床应用 | 省部级 | 教育部高校科研成果奖(科学技术、人文社科) | 二等奖 | 2016-02-26 | 国家教育部 | 是 | 1 | 2 | |
2 | 2016-J-25301-2-01-R02 | 胰岛素瘤诊治体系的建立及临床应用 | 国家级 | 国家最高科学技术奖、自然科学奖、技术发明奖、科技进步奖 | 二等奖 | 2016-12-21 | 国家科技部 | 是 | 1 | 2 | |
3 | 2008-J-253-2-03-R03 | 胰腺癌综合诊治方案的基础研究与临床应用 | 国家级 | 国家最高科学技术奖、自然科学奖、技术发明奖、科技进步奖 | 二等奖 | 2008-12-03 | 国家科技部 | 是 | 1 | 3 | |
4 | 2015医-1-005-02 | 胰岛素瘤诊治体系的建立及临床应用 | 省部级 | 科技进步奖、哲学社科奖 | 一等奖 | 2015-12-01 | 北京市人民政府 | 是 | 1 | 2 |
# | 成果类型 | 项目/专利/新品种名称 |
---|---|---|
1 | 作为主创人员获得授权的发明专利和新品种 | CHIP蛋白在胰腺癌治疗中的用途 |
2 | 作为主创人员获得授权的发明专利和新品种 | CHIP蛋白在胰腺癌早期诊断以及预后判断中的用途 |
3 | 作为主创人员获得授权的发明专利和新品种 | 胰腺癌动物模型的构建方法 |
4 | 作为主创人员获得授权的发明专利和新品种 | 一种人胰腺癌组织类器官模型的构建方法 |
5 | 出版高水平专著 | 加速康复外科理论与实践 |
6 | 出版高水平专著 | 内分泌外科学 |
7 | 出版高水平专著 | 曾宪九胰腺病学 |
8 | 出版高水平专著 | 消化系统与疾病 |
9 | 出版高水平专著 | 外科学(第2版) |
10 | 出版高水平专著 | 加速康复外科 |
11 | 作为主创人员获得授权的发明专利和新品种 | 一种人胰腺癌组织类器官模型的构建方法 |
12 | 作为主创人员获得授权的发明专利和新品种 | 一种用于胰腺癌早期诊断的生物标志物及应用 |
13 | 作为主创人员获得授权的发明专利和新品种 | CHIP蛋白在胰腺癌治疗中的用途 |